- Home
- DSP vs TVRD Comparison
DSP vs TVRD Comparison
Compare DSP & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- TVRD
- Stock Information
- Founded
- DSP 1999
- TVRD 2017
- Country
- DSP United States
- TVRD United States
- Employees
- DSP N/A
- TVRD N/A
- Industry
- DSP EDP Services
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- TVRD Health Care
- Exchange
- DSP Nasdaq
- TVRD Nasdaq
- Market Cap
- DSP 220.3M
- TVRD 246.5M
- IPO Year
- DSP 2021
- TVRD N/A
- Fundamental
- Price
- DSP $14.60
- TVRD $26.52
- Analyst Decision
- DSP Strong Buy
- TVRD Strong Buy
- Analyst Count
- DSP 8
- TVRD 5
- Target Price
- DSP $21.75
- TVRD $59.20
- AVG Volume (30 Days)
- DSP 159.3K
- TVRD 63.2K
- Earning Date
- DSP 08-11-2025
- TVRD 08-21-2025
- Dividend Yield
- DSP N/A
- TVRD N/A
- EPS Growth
- DSP N/A
- TVRD N/A
- EPS
- DSP 0.13
- TVRD N/A
- Revenue
- DSP $306,484,000.00
- TVRD N/A
- Revenue This Year
- DSP $18.36
- TVRD N/A
- Revenue Next Year
- DSP $15.95
- TVRD N/A
- P/E Ratio
- DSP $112.61
- TVRD N/A
- Revenue Growth
- DSP 30.64
- TVRD N/A
- 52 Week Low
- DSP $8.70
- TVRD $8.13
- 52 Week High
- DSP $26.33
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- DSP 62.20
- TVRD N/A
- Support Level
- DSP $13.32
- TVRD N/A
- Resistance Level
- DSP $13.95
- TVRD N/A
- Average True Range (ATR)
- DSP 0.50
- TVRD 0.00
- MACD
- DSP 0.11
- TVRD 0.00
- Stochastic Oscillator
- DSP 93.01
- TVRD 0.00
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.